CD274 and non-small cell lung carcinoma: Further studies found that elderly patients with advanced NSCLC in the PD-L1 high expression subgroup benefited from treatment with ICIs in combination with anti-angiogenic agents (PFS: P=0.017), suggesting PD-L1 ≥50% as a potential benefit marker in this population.